AUM Biosciences will be at BIO International Convention 2019, Philadelphia.
Pennsylvania Convention Center, Philadelphia, PA, 3 - 6 June 2019.
The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.
BIO attracts 16,000+ biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. We bring together a wide spectrum of life science and application areas including drug discovery, bio manufacturing, genomics, bio fuels, nano-technology and cell therapy.
For details about the event visit https://convention.bio.org/
About AUM Biosciences
AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. Dedicated to unlocking the value in innovation, AUM harnesses the power of precision medicine and digital health to support patients, physicians and partners. AUM focuses on earlystage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets.
AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs. AUM Biosciences is led by a highly-experienced management team with over 75 years of high-quality oncology drug development experience combined.
Headquartered in Singapore, AUM is strategically positioned to work, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally. AUM is the recipient of Frost & Sullivan’s 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year. For more information, please visit www.aumbiosciences.com